Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

436.70 +2.69 (+0.62%)
Streaming Delayed Price Updated: 12:41 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
68 69 Next >
News headline image
The Ultimate Growth Stock to Buy With $1,000 Right Now ↗
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
5 Top Stocks to Buy in January ↗
Start the year off right by investing in these quality businesses. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals Stock a Buy Now? ↗
The biotech's prospects keep improving. 
Via The Motley Fool
News headline image
Investing Trends to Follow in 2024 ↗
We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one. 
Via The Motley Fool
News headline image
Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗
With a new medicine on the market and plenty of money, Vertex is in great shape. 
Via The Motley Fool
News headline image
Market Whales and Their Recent Bets on VRTX Options ↗
 
Via Benzinga
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
2 Biotech Stocks With Huge Catalysts in 2024 ↗
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
News headline image
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors ↗
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
News headline image
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
It's not too late to get in on these market beaters. 
Via The Motley Fool
News headline image
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
News headline image
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway. ↗
These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly. 
Via The Motley Fool
Topics Stocks
News headline image
3 Biotech Stocks Set for Breakthroughs in 2024 ↗
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
News headline image
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
News headline image
Prediction: These 3 Stocks Will Soar in 2024 ↗
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
News headline image
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
News headline image
Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade. ↗
These stocks offer attractive risk-reward profiles. 
Via The Motley Fool
News headline image
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now ↗
It's been a crazy year across sectors, but winners remain. 
Via The Motley Fool
News headline image
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
News headline image
3 Monster Stocks to Buy Without Any Hesitation ↗
These are easy choices for investors seeking market-beating long-term gains. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
News headline image
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗
Editas isn't out of the woods yet, but it's better off than before. 
Via The Motley Fool
News headline image
1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗
The stock has been in the news lately. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy With Your End-of-the-Year Bonus ↗
Your bonus could become the gift that keeps on giving. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.